Chinese Biopharmaceuticals: The first patient has been enrolled in the phase III registration clinical trial of the use of the monoclonal antibody "CCR8 antibody" as a second-line treatment for stage III gastric cancer.

On the morning of May 7th, China Biopharmaceuticals announced on the Hong Kong Stock Exchange that its wholly-owned subsidiary, Lifan Pharmaceutical Technology Co., Ltd., has successfully completed the enrollment of the first patient in the Phase III clinical trial of the national first-class innovative drug KFQ-1 monoclonal antibody "CCR8 monoclonal antibody" combined with PD-1 inhibitor for second-line treatment of locally advanced or metastatic gastric cancer/gastroesophageal junction adenocarcinoma with CCR8 positivity. This study is the second key registration clinical trial conducted by LM-108.